CADTH | Evidence Driven
CADTH | Evidence Driven

Venclexta in combo Rituximab for Chronic Lymphocytic Leukemia – Details

Details

Files
Generic Name:
Venetoclax
Project Status:
Complete
Therapeutic Area:
Chronic Lymphocytic Leukemia (CLL)
Manufacturer:
AbbVie Corporation
Brand Name:
Venclexta in combo Rituximab
Project Line:
Reimbursement Review
Project Number:
PC0162-000
NOC Status at Filing:
Post NOC
Tumour Type:
Leukemia
Indications:
Chronic Lymphocytic Leukemia (CLL)
Funding Request:
In combination with rituximab (V+R) is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy
Sponsor:
AbbVie Corporation
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Venetoclax (Venclexta) in combo Rituximab CLL – pERC Final Recommendation Final Recommendation May 31, 2019 View PDF
Venetoclax (Venclexta) in combo Rituximab CLL – Final Economic Guidance Report Guidance Reports May 31, 2019 View PDF
Venetoclax (Venclexta) in combo Rituximab CLL – Final Clinical Guidance Report Guidance Reports May 31, 2019 View PDF
Venetoclax (Venclexta) in combo Rituximab CLL - pERC Initial Recommendation Initial Recommendation April 4, 2019 View PDF
Venetoclax (Venclexta) in combo Rituximab CLL – PAG Feedback on Initial Recommendation Feedback May 31, 2019 View PDF
Venetoclax (Venclexta) in combo Rituximab CLL – Manufacturer Feedback on Initial Recommendation Feedback May 31, 2019 View PDF
Venetoclax (Venclexta) in combo Rituximab CLL – Patient Advocacy Group Feedback on Initial Recommendation Feedback May 31, 2019 View PDF
Venetoclax (Venclexta) in combo Rituximab CLL – Clinician Feedback on Initial Recommendation Feedback May 31, 2019 View PDF
Venetoclax (Venclexta) in combo Rituximab CLL – Patient Advocacy Group COI Declarations COI Declarations May 31, 2019 View PDF
Venetoclax (Venclexta) in combo Rituximab CLL – Clinician COI Declarations COI Declarations May 31, 2019 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : June 17, 2019